Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease

Inclusion Criteria: * Males age \> 40 years. * Subjects must have chronic stable angina, meeting the labeled indications for ranolazine: Ranolazine is indicated for the treatment of chronic angina. Ranolazine should be reserved for subjects who have not achieved an adequate response with other anti-anginal drugs. * Subjects must have a resting ankle brachial index (ABI) of \< 0.90 with a post-exercise decrement of ≥ 10% in at least one leg, OR a resting ABI of ≥0.90 to ≤ 1.00 with a post-exercise decrement of ≥ 20% in at least one leg * The subject has provided written informed consent to participate, understands the requirements of the study, and agrees to return for the required assessments Exclusion Criteria: * Non-atherosclerotic diseases of the peripheral circulation by clinical history * Unable to complete the first stage of the modified, extended Astrand treadmill protocol * Clinically significant ECG abnormalities or changes with exercise on the screening ECG * Evidence of critical limb ischemia (CLI) * Hepatic impairment (Child-Pugh Classes A \[mild\], B \[moderate\], or C \[severe\]) * End stage renal disease requiring dialysis * Hemoglobin \< 12 mg/dL. * Platelet count \< 90,000/mL. * Planned surgical/endovascular intervention for coronary artery disease (CAD) or peripheral arterial disease (PAD) in the next 3 months * Maximal exercise is limited by symptoms other than claudication or angina * Significant mental illness or drug abuse within 30 days of enrollment that in the opinion of the Investigator could impact the subject's ability to successfully complete the trial * Known allergy to ranolazine * Pre-existing QTc prolongation on a resting electrocardiogram (ECG) at Screening due to the risk of worsening of this condition with the use of ranolazine * Treatment with QT prolonging drugs such as Class IA (e.g. quinidine) and Class III (e.g. sotalol, dofetilide), antiarrhythmics, amiodarone, and antipsychotics (e.g. thioridazine, ziprasidone) * Treatment with potent or moderately potent CYP3A inhibitors including ketoconazole and other azole antifungals, diltiazem, verapamil, macrolide antibiotics, cyclosporine, or human immunodeficiency virus (HIV) protease inhibitors * The subject has previously received ranolazine within the 6-months prior to enrollment * The subject has received an investigational drug within 90 days prior to enrollment * Type 1 or type 2 diabetes mellitus * Congestive Heart Failure, ≥ New York Heart Association (NYHA) Class…